Exenatide may aggravate moderate diabetic renal impairment: a case report
Open accessThe DOI matches its Crossref record.
Abstract
We write in response to a recently published paper in this journal [1] in which mainly nondiabetic patients with renal impairment, without polypharmacy, were evaluated using exenatide.The study concluded that subjects with mild to moderate renal impairment were able to tolerate the drug.However, whether this is the case for patients with Type 2 diabetes remains uncertain, and we present a case that highlights potential problems.Exenatide 5 mg b.i.d. was given to one male patient (66 years, body mass index 35.1 kg m -2 ) with Type 2 diabetes since 1992,who in 1995 was diagnosed with microalbuminuria.By 1998 he had developed macroalbuminuria, in 2000 his creatinine levels exceeded upper limits of normal and in 2004 he had developed renal impairment-related anaemia and metabolic bone disease.Other complications were proliferative retinopathy (diagnosed 1995), peripheral sensory neuropathy (since 1996) and gout ( since 2007).Concomitant medications were losartan potassium 25 mg q.d., furosemide 40 mg b.i.d., spirinolactone 50 mg q.d., alfacalcidol 0.25 mg 3 days week -1 , darbepoetin alfa 20 mg month -1 , allopurinol 100 mg q.d., biphasic insulin aspart 30 b.i.d.[40-42 units (U) breakfast, 60-66 U dinner] and insulin aspart q.d.(10 U lunch).Due to non-optimal glycaemic control the patient was given exenatide (February 2008) after careful explanation that this was considered off-label use, since he was taking insulin.In the following 4 weeks the patient's creatinine levels rose (192 to 244 mmol l -1 ) and, correspondingly, the Cockroft-Gault [2] creatinine clearance (CrCL) was reduced (53.1 to 41.8 mg min -1 , Figure 1).Reductions were also seen in HbA1c, fasting plasma glucose (respectively 7.6 to 6.8% and 7.2 to 5.1 mmol l -1 ) and total daily insulin dosages (by 40%).The worsening of renal impairment was not related to urinary tract infection, obstruction or dehydration, although he experienced some nausea and diarrhoea.Hence, exenatide was stopped, and within the next 2 weeks his kidney function parameters returned to pretreatment levels (creatinine 196 mmol l -1 , CrCL 52.1 mg min -1 ).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Adverse drug reactions of GLP-1 agonists: A systematic review of case reports
Shetty, R., Basheer, F. T., Poojari, P. G., Thunga, G., Chandran, V. P., & Acharya, L. D. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102427 · Cited by 145
Management of diabetes mellitus in patients with chronic kidney disease
Hahr, A. J., & Molitch, M. E. (2015) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-015-0001-9 · Cited by 142
Metadata
- Authors
- Johansen, O. E., & Whitfield, R.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2008-09-11
- Volume
- 66
- Issue
- 4
- Pages
- 568-569
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1975996626
- Cited by
- 44
- References
- 0
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exenatide may aggravate moderate diabetic renal impairment: a case report. https://app.cochat.ai/papers/10.1111/j.1365-2125.2008.03221.x
- The paper
- Johansen, O. E., & Whitfield, R. (2008). Exenatide may aggravate moderate diabetic renal impairment: a case report. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2008.03221.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.